Departments of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria.
Liver Transpl. 2013 Aug;19(8):879-86. doi: 10.1002/lt.23678. Epub 2013 Jul 25.
Acute-on-chronic liver failure (ACLF) is characterized by high short-term mortality. Liver transplantation (LT) is a potential therapy for patients who do not improve with supportive measures, but the efficacy of LT has not been shown. The aim of this study was to investigate the feasibility of LT and to determine the postoperative outcomes of patients with ACLF. All patients referred to our liver unit between 2002 and 2010 were registered in a database. The diagnosis of ACLF was made in accordance with the Asian Pacific Association for the Study of the Liver consensus. The post-LT outcomes were compared with the outcomes of a cohort of patients with chronic liver disease who underwent transplantation for other indications during the same period. One hundred forty four of 238 patients fulfilled the ACLF criteria. In an intention-to-treat analysis, the median transplant-free survival time was 48 days. Multiorgan failure was the most common cause of death. Ninety-four patients (65%) were evaluated for LT, 71 patients (49%) were listed, and 33 patients (23%) finally underwent deceased donor LT; this resulted in a wait-list mortality rate of 54%. Patients who developed infectious complications (particularly pneumonia and/or sepsis) and patients who received renal replacement therapy or mechanical ventilation were less likely to undergo LT. The 1- and 5-year survival rates of 87% and 82% were comparable to the rates for non-ACLF patients. In conclusion, this study shows that LT remains the only therapeutic option for the vast majority of patients with ACLF. However, LT was feasible in less than one fourth of the patients with a 5-year survival rate greater than 80%.
慢加急性肝衰竭(ACLF)的特点是短期死亡率高。肝移植(LT)是对支持治疗无效的患者的一种潜在治疗方法,但 LT 的疗效尚未得到证实。本研究旨在探讨 LT 的可行性,并确定 ACLF 患者的术后结果。2002 年至 2010 年间,所有转诊至我院肝科的患者均在数据库中登记。ACLF 的诊断符合亚太肝病学会共识。将 LT 后的结果与同期因其他原因接受移植的慢性肝病患者队列的结果进行比较。238 例患者中有 144 例符合 ACLF 标准。在意向治疗分析中,无移植生存时间中位数为 48 天。多器官衰竭是最常见的死亡原因。94 例(65%)患者接受 LT 评估,71 例(49%)患者入组,33 例(23%)最终接受了已故供体 LT;由此导致等待名单死亡率为 54%。发生感染性并发症(特别是肺炎和/或败血症)和接受肾脏替代治疗或机械通气的患者不太可能接受 LT。1 年和 5 年的生存率分别为 87%和 82%,与非 ACLF 患者的生存率相当。总之,本研究表明 LT 仍然是大多数 ACLF 患者的唯一治疗选择。然而,在接受 LT 的患者中,不到四分之一的患者 5 年生存率大于 80%。